This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gaetano Ciancio, University of Miami
ClinicalTrials.gov Identifier:
NCT01680861
First received: March 6, 2012
Last updated: October 21, 2016
Last verified: October 2016
March 6, 2012
October 21, 2016
November 2012
December 2014   (Final data collection date for primary outcome measure)
BPAR (Biopsy-proven Acute Rejection) Incidence During the First 12 Months Post-transplant [ Time Frame: 1 year ]
BPAR (biopsy-proven acute rejection) incidence during the first 12 months post-transplant. Grading is determined using standard Banff criteria.
Induction therapy [ Time Frame: 1 year ]
Induction therapy with ATG and basiliximab and corticosteroid withdrawal
Complete list of historical versions of study NCT01680861 on ClinicalTrials.gov Archive Site
  • Incidence of Chronic Allograft Nephropathy (CAI) at 12 Months Post-transplant [ Time Frame: 1 year ]
    Incidence of (biopsy-proven) chronic allograft nephropathy (CAI) [interstitial fibrosis and tubular atrophy, using standard Banff criteria] at 12 months post-transplant.
  • Graft Loss (Return to Permanent Dialysis or Death) [ Time Frame: during the first 12 months post-transplant ]
  • eGFR (Calculated Glomerular Filtration Rate), i.e., Renal Function, at 1 Month Post-transplant. [ Time Frame: at 1 month post-transplant ]
    using the abbreviated MDRD formula.
  • eGFR (Renal Function) at Month 3 Post-transplant [ Time Frame: at 3 months post-transplant ]
    Renal function as determined by the estimated glomerular filtration rate (eGFR) at 3 months post-transplant, using the abbreviated MDRD formula.
  • eGFR (Renal Function) at 6 Months Post-transplant [ Time Frame: at 6 months post-transplant ]
    using the abbreviated MDRD formula.
  • Discontinuance of Any Study Medication (Tacrolimus, Everolimus, or EC-MPS) [ Time Frame: during the first 12 months post-transplant ]
BPAR rate [ Time Frame: 1 year ]
BPAR rate at 12 months as the single, primary study endpoint
Not Provided
Not Provided
 
Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium
Randomized, Open-Label Trial of Tacrolimus/Everolimus vs. Tacrolimus/Enteric-Coated Mycophenolate Sodium to Prevent Biopsy-Proven Acute Rejection and Chronic Allograft Injury in Adult, Primary Kidney Transplantation
A recent therapeutic strategy following renal transplantation includes simultaneous use of reduced calcineurin inhibitor (CNI) dosing and maximized use of a non-nephrotoxic, antiproliferative drug (inosine monophosphate dehydrogenase (IMPDH) or TOR inhibitor), with the goals of reducing/avoiding CNI nephrotoxicity, the incidence of acute rejection, and chronic allograft injury (CAI) (i.e., interstitial fibrosis/tubular atrophy), leading to more favorable longer-term patient and graft survival.1-7 Early corticosteroid withdrawal has also been used in the attempt to avoid well-known side effects while maintaining favorable patient and graft survival.8-10 While the investigators center and numerous other centers have also included single agent, antibody induction utilizing the lymphodepleting polyclonal antibody rabbit anti-human thymocyte globulin (ATG), nondepleting human anti-interleukin-2 receptor (CD25) monoclonal antibody daclizumab (Dac) or basiliximab, or lymphodepleting humanized anti-CD52 monoclonal antibody alemtuzumab,11-17 evidence now suggests that an even more effective induction strategy may include the combined use of more than one induction agent (each with fewer doses than if used alone), with the goal of bringing the kidney transplant recipient even closer (through more effectively timed lymphodepletion) to an optimally immunosuppressed state, allowing further reduction in long-term maintenance drug dosing.18-25 The investigators have now successfully used dual ATG/Dac induction therapy in both kidney-alone23-24 and simultaneous kidney-pancreas (SPK) transplantation,18-20 and a recent report from the investigators center of kidney-alone and SPK recipients shows that the addition of anti-CD25 to ATG for induction therapy more effectively delays the return of peripheral blood CD25+ cells.25 In the kidney-alone recipient study 3 doses of ATG were combined with 2 doses of Dac for induction,23-24 vs. the investigators previous studies utilizing single agent induction with 7 doses of ATG or 5 doses of Dac.4,16,17 Successful combination of ATG/basiliximab as dual induction in kidney transplantation has also been reported elsewhere,21-22 along with equivalency in clinical outcomes using daclizumab vs. basiliximab.13

A. Primary Objectives:

  1. The percentage of patients who develop chronic allograft injury (CAI) progression during the first 12 months post-transplant protocol biopsy (i.e., higher grade of IF/TA at either the 6 or 12 month protocol biopsy in comparison with the baseline biopsy).
  2. The incidence rate of biopsy-proven acute rejection (BPAR) during the first 12 months post-transplant.

B. Secondary Objectives:

  1. Adverse events including graft loss (death-censored and death-uncensored), and death at 12 months post-transplant.
  2. Incidence rate and severity (severity of CAI at 12 months as well), based upon careful review of all clinically indicated and protocol biopsies.
  3. Renal function as determined by serum creatinine and estimated glomerular filtration rate (eGFR) (calculated using the abbreviated MDRD formula) at 12, months post-transplant. Use of multivariable analysis to compare renal function as well as BPAR and CAI progression will also be performed (particularly, after adjusting for the significant effects of donor age, recipient age, race/ethnicity, and any other predictors).

5. Adverse events including withholding (for ≥ 28 days) or discontinuance of study medications (and reasons why), new onset diabetes mellitus after transplantation (NODAT), infections requiring hospitalization, and requirement of anti-lipid medication at 12 months post-transplant.

6. Avoidance of the requirement for maintenance corticosteroid therapy after renal transplantation.

7. Allowance of reduced maintenance tacrolimus dosing (rTd).

Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Transplant; Failure, Kidney
  • Drug: Tacrolimus
    Tacrolimus dosing (rTd) is planned, 0.1 mg/kg PO BID - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.
    Other Name: Prograf (brand name)
  • Drug: Everolimus
    Everolimus initiated at 0.75 PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml.
    Other Name: Zortress (brand name)
  • Drug: Enteric Coated Mycophenolate Sodium (EC-MPS)
    EC-MPS 720 mg PO BID - beginning on 1st postoperative day.
    Other Name: Myfortic (brand name)
  • Drug: Corticosteroids
    Corticosteroids will be given as per our center protocol, i.e., a bolus of 500 mg of Methylprednisolone intravenously at surgery and daily x2, followed by 1.0 mg/kg, then 0.5 mg/kg orally until weaned off completely by 7-10 days postoperatively - the plan is for corticosteroids to be discontinued by 7-10 days postoperatively in both groups.
    Other Name: Methylprednisolone
  • Experimental: Tacrolimus and Everolimus

    Patients in both arms will receive reduced tacrolimus dosing (rTd), 0.1 mg/kg PO divided in two daily doses - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.

    Everolimus initiated within 24 hours post-transplant (i.e., immediately following randomization) at 0.75mg PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml.

    Interventions:
    • Drug: Tacrolimus
    • Drug: Everolimus
    • Drug: Corticosteroids
  • Active Comparator: Tacrolimus and Enteric-Coated Mycophenolate Sodium (EC-MPS)

    Patients in both arms will receive reduced tacrolimus dosing (rTd), 0.1 mg/kg PO divided in two daily doses - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.

    EC-MPS will be initiated at 720 mg PO BID starting on the first post-operative day.

    Interventions:
    • Drug: Tacrolimus
    • Drug: Enteric Coated Mycophenolate Sodium (EC-MPS)
    • Drug: Corticosteroids
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
32
December 2014
December 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Weight > 40 kg.
  • Deceased donor (SCD) or LD.
  • Donor-recipient 1 haplotype matched pairs with a minimum matching of 1 HLA DR antigen.
  • Negative standard cross match for T cells.
  • Pretransplant panel reactive antibodies of < 30%.
  • Graft required to be functional, producing at least 100ml of urine within 24hr after transplantation.

Exclusion Criteria:

  • Previously received or is receiving an organ transplant other than a kidney.
  • Donor organ with a cold ischemic time > 48 hours.
  • ABO incompatible donor kidney.
  • Recipients of T cell, or B cell crossmatch positive transplant.
  • Panel reactive antibody (PRA) >30%
  • HIV or Hepatitis C virus, or Hepatitis B virus antigenemia.
  • Current malignancy or a history of malignancy
  • Liver disease
  • Uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or an active peptic ulcer
  • Use of warfarin, fluvastatin, or herbal supplements during the study.
  • Use of astemizole, pimozide, cisapride, terfenadine, or ketoconazole.
  • Hypersensitivity to thymoglobulin, IL-2 receptor inhibitor monoclonal antibodies, tacrolimus, everolimus, MPA, or corticosteroids.
  • Pregnant or lactating.
  • Abnormal screening/baseline labs WBC, platelet count, triglycerides, and cholesterol Double kidneys,ECD, pediatric en-block, and donation after cardiac death (DCD)
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01680861
20110126
Yes
Not Provided
No
Not Provided
Gaetano Ciancio, University of Miami
Gaetano Ciancio
Not Provided
Principal Investigator: Gaetano Ciancio, M.D. University of Miami
University of Miami
October 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP